Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer
Journal of the National Comprehensive Cancer Network · 2023-01 · 21 (1) · 33-41.e16
DOI: 10.6004/jnccn.2022.7065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2023-01. Verfasst von Matteo Lambertini und 27 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Genova, Genova, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Ovarian Reserve. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Medical Research Council.
Abstract (Originalsprache)
Background
The potential gonadotoxicity of anti-HER2 agents remains largely unknown, and limited, conflicting evidence exists for taxanes. Antimüllerian hormone (AMH) is an established biomarker of ovarian reserve that may aid in quantifying anticancer treatment–induced gonadotoxicity. Patients and Methods: The present biomarker analysis of the randomized phase III neoadjuvant NeoALTTO trial included premenopausal women aged ≤45 years at diagnosis of HER2-positive early breast cancer with available frozen serum samples at baseline (ie, before anticancer treatments), at week 2 (ie, the “biological window” of anti-HER2 therapy alone), and/or at the time of surgery (ie, after completing paclitaxel + anti-HER2 therapy, before starting adjuvant chemotherapy).
Results
The present analysis included 130 patients with a median age of 38 years (interquartile ratio [IQR], age 33–42 years). AMH values at the 3 time points differed significantly ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, University of Genova, Genova, Italy.
- UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
- IRCCS Ospedale Policlinico San Martino, Genova, Italy.
- MRC Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, United Kingdom.
- Institute of Genomics and Cancer, The University of Edinburgh, Edinburgh, United Kingdom.
- Gustave Roussy, Villjuif, France.
Förderung
- Medical Research Council
Zitieren
APA
Lambertini, M., Ceppi, M., Anderson, R. A., Cameron, D. A., Bruzzone, M., Franzoi, M. A., Massarotti, C., El-Abed, S., Wang, Y., Lecocq, C., Nuciforo, P., Rolyance, R., Pusztai, L., Sohn, J., Latocca, M. M., Arecco, L., Pistilli, B., Ruddy, K. J., Ballestrero, A., …, & Demeestere, I. (2023). Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer. Journal of the National Comprehensive Cancer Network, 21(1), 33-41.e16. https://doi.org/10.6004/jnccn.2022.7065
Vancouver
Lambertini M, Ceppi M, Anderson RA, Cameron DA, Bruzzone M, Franzoi MA, et al. Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer. Journal of the National Comprehensive Cancer Network. 2023;21(1):33-41.e16. doi:10.6004/jnccn.2022.7065
BibTeX
@article{Lambertini2023,
author = {Lambertini, Matteo and Ceppi, Marcello and Anderson, Richard A and Cameron, David A and Bruzzone, Marco and Franzoi, Maria Alice and Massarotti, Claudia and El-Abed, Sarra and Wang, Yingbo and Lecocq, Christophe and Nuciforo, Paolo and Rolyance, Rebecca and Pusztai, Lajos and Sohn, Joohyuk and Latocca, Maria Maddalena and Arecco, Luca and Pistilli, Barbara and Ruddy, Kathryn J and Ballestrero, Alberto and Del Mastro, Lucia and Peccatori, Fedro A and Partridge, Ann H and Saura, Cristina and Untch, Michael and Piccart, Martine and Di Cosimo, Serena and de Azambuja, Evandro and Demeestere, Isabelle},
title = {Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2023},
volume = {21},
number = {1},
pages = {33--41.e16},
doi = {10.6004/jnccn.2022.7065}
}
EUVIMED